Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Current Deferred Revenue (2021 - 2025)

Lyra Therapeutics has reported Current Deferred Revenue over the past 5 years, most recently at $11.9 million for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $11.9 million for Q4 2025, up 2880.4% from a year ago — trailing twelve months through Dec 2025 was $11.9 million (up 2880.4% YoY), and the annual figure for FY2025 was $11.9 million, up 2880.4%.
  • Current Deferred Revenue for Q4 2025 was $11.9 million at Lyra Therapeutics, roughly flat from $11.9 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for LYRA hit a ceiling of $14.9 million in Q1 2023 and a floor of $216000.0 in Q1 2025.
  • Median Current Deferred Revenue over the past 5 years was $2.5 million (2022), compared with a mean of $5.9 million.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 91.17% in 2024 and later soared 2880.4% in 2025.
  • Lyra Therapeutics' Current Deferred Revenue stood at $11.7 million in 2021, then tumbled by 89.12% to $1.3 million in 2022, then skyrocketed by 30.04% to $1.7 million in 2023, then crashed by 76.0% to $398000.0 in 2024, then soared by 2880.4% to $11.9 million in 2025.
  • The last three reported values for Current Deferred Revenue were $11.9 million (Q4 2025), $11.9 million (Q3 2025), and $11.9 million (Q2 2025) per Business Quant data.